RLSC.CN - RISE Life Science Corp.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.315
-0.045 (-12.50%)
As of 9:44AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.360
Open0.365
Bid0.330 x 0
Ask0.365 x 0
Day's Range0.315 - 0.365
52 Week Range0.130 - 0.740
Volume13,737
Avg. Volume40,253
Market Cap16.724M
Beta3.04
PE Ratio (TTM)N/A
EPS (TTM)-0.111
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile10 days ago

    RISE Life Science Provides Operational Update

    Toronto, Ontario--(Newsfile Corp. - June 8, 2018) - RISE Life Science Corp. (CSE: RLSC) (the "Company" and/or "RISE"), today provided an operational update on its plans and projected timelines for the 2018 calendar year. RISE is pleased to announce that it expects to launch its own commercial products for sale in the California market on or about its previously announced launch date of 6/20/2018."With the recent introduction of the RISE Report on SEX ...

  • Newsfile11 days ago

    RISE Life Science Corp. to Acquire California CDB Company Life Bloom Organics and Leading Cannabis Brand Strategy Agency Cultivate Kind

    Toronto, Ontario--(Newsfile Corp. - June 7, 2018) - RISE Life Science Corp. (CSE: RLSC) (the "Company" and/or "RISE")  is pleased to announce that it has signed a Letter of Intent (LOI) to acquire 100% of Life Bloom Organics, LLC, a California company that produces and markets organic oral sprays containing CBD, and 100% of Cultivate Kind, one of the top marketing and branding agencies for the cannabis industry in the United States."This represents a ...

  • GlobeNewswire25 days ago

    RISE Life Science: Commitment to the Highest Quality Cannabis Products for Sexual Health and Wellness -- CFN Media

    CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing RISE Life Science Corp. (CSE:RLSC), the importance of consistent high quality in the emerging cannabis market, and the company’s commitment to best practices, ingredients, and science. As the cannabis industry matures, both in North America and across the globe, regulations and consumer demands will require companies to produce consistent, high quality products that are safe and effective. Gone are the days of illicit weed grown with questionable practices, as the black market is being replaced by regulated operations offering a variety of cannabis products scientifically developed for use in distinct applications.

  • Newsfile2 months ago

    RISE Life Science Corp. Announces the RISE Report: A Study to Explore Cannabis Use and Sexual Health

    Study to reveal the health benefits of cannabis products and their relation to sexual health Toronto, Ontario--(Newsfile Corp. - April 24, 2018) - RISE Life Science Corp. (CSE: RLSC) (formerly Luminor Medical Technologies Inc.) (the "Company" and/or "RISE") today announced that it has commissioned a longitudinal study to investigate sexual function and health concerns, and, how cannabis products designed for sexual enhancement and health affect sexual behaviors and performance. The RISE Report on Cannabis ...

  • Newsfile2 months ago

    RISE Life Science Corp. Announces Closing $2.2M of Equity Financing

    Toronto, Ontario--(Newsfile Corp. - April 19, 2018) - RISE Life Science Corp. (CSE: RLSC) (formerly Luminor Medical Technologies Inc. (the "Company" or "RISE") is pleased to announce that, further to it press release dated March 29, 2018, it has closed tranches (each a "Tranche") of its previously announced non-brokered private placement (the "Offering") through the issuance of an aggregate of 7,366,166 units (each a "Unit") at a price of $0.30 per Unit for gross ...

  • Newsfile3 months ago

    RISE Life Science Announces Private Placement of Units

    Toronto, Ontario--(Newsfile Corp. - March 29, 2018) - RISE Life Science Corp. (CSE: RLSC) (formerly Luminor Medical Technologies Inc.) (the "Company") announces that it intends to complete a non-brokered private placement of up to 10,000,000 units ("Units") at a price of $0.30 per Unit (the "Issue Price") for gross proceeds of up to $3,000,000 (the "Offering"). Each Unit will be comprised of one common share ("Common Share") of the Company and one-half of ...